Overview

Eszopiclone Treatment & Cortisol Responsivity

Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
This study was designed to use a sensitive neuroendocrine probe, the Dexamethasone/Corticotropin-Releasing Hormone (DEX/CRH) test, in a sample of healthy adults with insomnia. The primary aim was to assess cortisol reactivity before and after long-term (6 weeks) administration of eszopiclone. It was hypothesized that treatment with eszopiclone would result in a significant reduction in plasma cortisol response to the DEX/CRH test following treatment of insomnia with standard dose of eszopiclone.
Phase:
Phase 4
Details
Lead Sponsor:
Butler Hospital
Collaborator:
Sunovion
Treatments:
Eszopiclone
Hydrocortisone